| Invossa (tonogenchoncel-L) / Kolon Life Sci |
NCT03203330: A Study to Determine the Safety and Efficacy of TG-C in Subjects with Kellgren and Lawrence Grade 2 or 3 OA of the Knee |
|
|
| Active, not recruiting | 3 | 535 | US | TG-C, TissueGene-C, Placebo Control, Normal Saline | Kolon TissueGene, Inc. | Degenerative Osteoarthritis | 06/24 | 07/26 | | |
NCT03291470: Study to Determine the Efficacy and Safety of TG-C in Subjects with Kellgren/Lawrence Grade 2 or 3 OA of the Knee |
|
|
| Active, not recruiting | 3 | 531 | US | TG-C, TissueGene-C, Placebo Control, Normal Saline | Kolon TissueGene, Inc. | Degenerative Osteoarthritis | 03/24 | 03/26 | | |
NCT05276011: A Study to Determine the Safety and Efficacy of TG-C in Subjects with Symptomatic Early Hip Osteoarthritis |
|
|
| Not yet recruiting | 2 | 255 | NA | TG-C, TissueGene-C, Placebo Control, Normal Saline | Kolon TissueGene, Inc. | Degenerative Osteoarthritis | 10/26 | 10/26 | | |
NCT03412864: A Post Marketing Surveillance Study of INVOSSA K Inj. |
|
|
| Active, not recruiting | N/A | 3000 | RoW | | Kolon Life Science | Osteoarthritis | 07/23 | 07/23 | | |
| KLS-2031 / Kolon Life Sci |
NCT04238793: Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy |
|
|
| Completed | 1/2 | 18 | US | KLS-2031, Placebo | Kolon Life Science | Neuropathic Pain From Lumbosacral Radiculopathy | 10/23 | 10/23 | | |
NCT05613569: A Long-term, 3-Year, Follow-up Study for Patients Completing the KS-GIG-001-01 Study |
|
|
| Active, not recruiting | 1/2 | 5 | US | KLS-2031 | Kolon Life Science | Lumbosacral Radiculopathy | 08/26 | 04/27 | | |
| TG-C LD / Juniper Bio, Kolon Life Sci |
NCT06144970: Study to Determine the Safety and Tolerability of TG-C in Subjects with Back Pain Due to Degenerative Disc Disease |
|
|
| Not yet recruiting | 1 | 24 | NA | TG-C High Dose, TG-C Mid Dose, TG-C Low Dose, Sham Control | Kolon TissueGene, Inc. | Degenerative Disc Disease | 11/27 | 11/27 | | |
